Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217922 | 0.94 | DUT (0.38) | DUTALDH1A1ACHEPAOX | |
| SCHEMBL10018323 | 0.92 | PAOX (0.41) | DUTALDH1A1ACHEPAOX | |
| SCHEMBL1454793 | 0.88 | ALDH1A1 (0.38) | DUTALDH1A1MAPTHPGDLMNA | |
| SCHEMBL14117936 | 0.85 | KDM4E (0.38) | DUT | |
| SCHEMBL4590603 | 0.84 | ALDH1A1 (0.41) | DUTALDH1A1LMNA | |
| SCHEMBL28516260 | 0.84 | DUT (0.39) | DUT | |
| SCHEMBL19397978 | 0.84 | DUT (0.35) | DUT | |
| SCHEMBL5536890 | 0.82 | ALDH1A1 (0.40) | DUTALDH1A1 | |
| SCHEMBL7484513 | 0.82 | DUT (0.38) | DUT | |
| SCHEMBL18119985 | 0.82 | DUT (0.35) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367129-A1 | Lipid Compounds and Uses Thereof | PFIZER (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4612129-A1 | LIPID COMPOUNDS AND USES THEREOF | Pfizer Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095179-A1 | LIPID COMPOUNDS AND USES THEREOF | PFIZER INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-3937917-B1 | ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS | UNIV OREGON STATE (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | OREGON STATE UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3937917-A1 | ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS | Oregon State University (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20220009944-A1 | ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2022-01-13 | — | — | US | disclosed |
| WO-2020185695-A1 | ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2020-09-17 | — | — | WO | disclosed |
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLEY Q (US) | 2003-06-05 | — | — | US | disclosed |
| US-6492412-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF SULFONAMIDE OR ALKANOY OR AMIDE DERIVATIVE CONTAINING HETERO OR AROMATIC RINGS TO TREAT OSTEOPOROSIS, OSTEOTOMY, CHILDHOOD IDIOPATHIC BOEN LOSS ETC. | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLY O (US) | 2002-02-07 | — | — | US | disclosed |
| US-6344485-B1 | Method for treating glaucoma | PFIZER INC. | 2002-02-05 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | disclosed |
| EP-1000619-A2 | Method for treating glaucoma | Pfizer Products Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| US-4960779-A | Pyrrole derivatives, and pharmaceutical compositions which contain them and pharmacological methods of use | RHONE-POULENC SANTE (FR) | 1990-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | DUT 2178/4885ALDH1A1 2216/4885ACHE 1213/4885 |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | DUT 2178/4885ALDH1A1 2216/4885ACHE 1213/4885 |
| US-20220009944-A1 | ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS | SLC6A2, NAPRT, SLC6A3 | DUT 43/4885ALDH1A1 1101/4885ACHE 314/4885 |
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | SLC6A2, NAPRT, SLC6A3 | DUT 43/4885ALDH1A1 1101/4885ACHE 314/4885 |
| US-20250367129-A1 | Lipid Compounds and Uses Thereof | POLN, PHOSPHO1, NPC1 | DUT 1105/4885ALDH1A1 1763/4885ACHE 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.